— AGMB-129 hit all primary and secondary endpoints in interim read-out from 44 patients after 12 weeks treatment — Detailed interim STENOVA results to be presented at future scientific conference — STENOVA clinical trial on track to report full results in the fourth quarter of 2025 — Open-label extension study initiated